Premium
CD169 + macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer
Author(s) -
Wu Andy C,
He Yaowu,
Broomfield Amy,
Paatan Nicoll J,
Harrington Brittney S,
Tseng HsuWen,
Beaven Elizabeth A,
Kiernan Deirdre M,
Swindle Peter,
Clubb Adrian B,
Levesque JeanPierre,
Winkler Ingrid G,
Ling MingTat,
Srinivasan Bhuvana,
Hooper John D,
Pettit Allison R
Publication year - 2016
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.4718
Subject(s) - prostate cancer , cd68 , macrophage , pathology , prostate , osteoclast , bone metastasis , metastasis , bone marrow , cancer , osteolysis , medicine , immunohistochemistry , immune system , cancer research , osteoimmunology , chemistry , immunology , in vitro , receptor , biochemistry , surgery , rankl , activator (genetics)
Abstract Skeletal metastases present a major clinical challenge for prostate cancer patient care, inflicting distinctive mixed osteoblastic and osteolytic lesions that cause morbidity and refractory skeletal complications. Macrophages are abundant in bone and bone marrow and can influence both osteoblast and osteoclast function in physiology and pathology. Herein, we examined the role of macrophages in prostate cancer bone lesions, particularly the osteoblastic response. First, macrophage and lymphocyte distributions were qualitatively assessed in patient's prostate cancer skeletal lesions by immunohistochemistry. Second, macrophage functional contributions to prostate tumour growth in bone were explored using an immune‐competent mouse model combined with two independent approaches to achieve in vivo macrophage depletion: liposome encapsulated clodronate that depletes phagocytic cells (including macrophages and osteoclasts); and targeted depletion of CD169 + macrophages using a suicide gene knock‐in model. Immunohistochemistry and histomorphometric analysis were performed to quantitatively assess cancer‐induced bone changes. In human bone metastasis specimens, CD68 + macrophages were consistently located within the tumour mass. Osteal macrophages (osteomacs) were associated with pathological woven bone within the metastatic lesions. In contrast, lymphocytes were inconsistently present in prostate cancer skeletal lesions and when detected, had varied distributions. In the immune‐competent mouse model, CD169 + macrophage ablation significantly inhibited prostate cancer‐induced woven bone formation, suggesting that CD169 + macrophages within pathological woven bone are integral to tumour‐induced bone formation. In contrast, pan‐phagocytic cell, but not targeted CD169 + macrophage depletion resulted in increased tumour mass, indicating that CD169 − macrophage subset(s) and/or osteoclasts influenced tumour growth. In summary, these observations indicate a prominent role for macrophages in prostate cancer bone metastasis that may be therapeutically targetable to reduce the negative skeletal impacts of this malignancy, including tumour‐induced bone modelling. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.